Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...
Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...
Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains ... treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.
GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...
GLP-1 receptor agonists, originally developed for managing type ... By reducing hunger and promoting a feeling of fullness, ...
Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.
By now, stories of people achieving their weight loss goals while taking Ozempic, Zepbound, or other GLP-1 receptor agonists abound—but that doesn’t mean everyone will shed pounds on these ...
A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...